{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:28:09Z","timestamp":1766748489041,"version":"3.45.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","award":["Further details on funding provided in text"],"award-info":[{"award-number":["Further details on funding provided in text"]}],"id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10067-025-07649-9","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:47:46Z","timestamp":1761284866000},"page":"4945-4953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in weight associated with tumor necrosis factor inhibition in psoriatic arthritis: results from a retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-0341","authenticated-orcid":false,"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry J.","family":"Sheane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. Longo DL, (ed) N Engl J Med 376(10):957\u2013970","key":"7649_CR1","DOI":"10.1056\/NEJMra1505557"},{"issue":"25","key":"7649_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585880","volume":"11","author":"P Gough","year":"2020","unstructured":"Gough P, Myles IA (2020) Tumor necrosis factor receptors: pleiotropic signaling complexes and their differential effects. Front Immunol 11(25):585880","journal-title":"Front Immunol"},{"issue":"8","key":"7649_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/rheumatology\/ken146","volume":"47","author":"GD Summers","year":"2008","unstructured":"Summers GD, Deighton CM, Rennie MJ, Booth AH (2008) Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47(8):1124\u20131131","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"7649_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/rheumatology\/kel127","volume":"45","author":"S Marcora","year":"2006","unstructured":"Marcora S, Casanova F, Williams E, Jones J, Elamanchi R, Lemmey A (2006) Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis. Rheumatology (Oxford) 45(11):1385\u20131388","journal-title":"Rheumatology (Oxford)"},{"issue":"7130","key":"7649_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445(7130):866\u2013873","journal-title":"Nature"},{"issue":"3","key":"7649_CR6","first-page":"518","volume":"24","author":"G Partsch","year":"1997","unstructured":"Partsch G, Steiner G, Leeb BF, Dunky A, Br\u00f6ll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24(3):518\u2013523","journal-title":"J Rheumatol"},{"issue":"8","key":"7649_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB et al (2022) Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(8):465\u2013479","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"7649_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, De Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7649_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) 2018 American college of rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 71(1):5\u201332","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"7649_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","volume":"10","author":"S Mantravadi","year":"2017","unstructured":"Mantravadi S, Ogdie A, Kraft WK (2017) Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 10(8):899\u2013910","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"7649_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3899\/jrheum.100919","volume":"38","author":"L Eder","year":"2011","unstructured":"Eder L, Chandran V, Gladman DD (2011) Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol 38(6):1066\u20131070","journal-title":"J Rheumatol"},{"issue":"8","key":"7649_CR12","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/art.22805","volume":"56","author":"D van der Heijde","year":"2007","unstructured":"van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C et al (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 56(8):2698\u20132707","journal-title":"Arthritis Rheum"},{"doi-asserted-by":"crossref","unstructured":"van der Heijde D, Klareskog L, Landew\u00e9 R, Bruyn GAW, Cantagrel A, Durez P et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56(12):3928\u201339","key":"7649_CR13","DOI":"10.1002\/art.23141"},{"doi-asserted-by":"crossref","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T et al (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 15(10):i\u2013xxi, 1\u2013329","key":"7649_CR14","DOI":"10.3310\/hta15100"},{"issue":"3","key":"7649_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","volume":"7","author":"A Kumthekar","year":"2020","unstructured":"Kumthekar A, Ogdie A (2020) Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther 7(3):447\u2013456","journal-title":"Rheumatol Ther"},{"issue":"1","key":"7649_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","volume":"52","author":"A Russolillo","year":"2013","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N et al (2013) Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 52(1):62\u201367","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7649_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MND Di Minno","year":"2013","unstructured":"Di Minno MND, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R et al (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 65(1):141\u2013147","journal-title":"Arthritis Care Res"},{"issue":"6","key":"7649_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MND Di Minno","year":"2014","unstructured":"Di Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R et al (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis 73(6):1157\u20131162","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7649_CR19","first-page":"855","volume":"35","author":"K Briot","year":"2008","unstructured":"Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 35(5):855\u2013861","journal-title":"J Rheumatol"},{"issue":"9","key":"7649_CR20","first-page":"570","volume":"54","author":"AH Ehsani","year":"2016","unstructured":"Ehsani AH, Mortazavi H, Balighi K, Hosseini MS, Azizpour A, Hejazi SP et al (2016) Changes in body mass index and lipid profile in psoriatic patients after treatment with standard protocol of infliximab. Acta Med Iran 54(9):570\u2013575","journal-title":"Acta Med Iran"},{"issue":"3","key":"7649_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","volume":"22","author":"P Gisondi","year":"2008","unstructured":"Gisondi P, Cotena C, Tessari G, Girolomoni G (2008) Anti\u2013tumour necrosis factor-\u03b1 therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Acad Dermatol Venereol 22(3):341\u2013344","journal-title":"Acad Dermatol Venereol"},{"issue":"2","key":"7649_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/jdv.12066","volume":"28","author":"E Mah\u00e9","year":"2014","unstructured":"Mah\u00e9 E, Reguiai Z, Barthelemy H, Quiles-Tsimaratos N, Chaby G, Girard C et al (2014) Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. Acad Dermatol Venereol 28(2):151\u2013159","journal-title":"Acad Dermatol Venereol"},{"issue":"9","key":"7649_CR23","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1185\/03007990903162465","volume":"25","author":"F Prignano","year":"2009","unstructured":"Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F et al (2009) Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 25(9):2311\u20132316","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"7649_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","volume":"24","author":"LDI Renzo","year":"2011","unstructured":"Renzo LDI, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A et al (2011) Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment. Dermatol Ther 24(4):446\u2013451","journal-title":"Dermatol Ther"},{"issue":"4","key":"7649_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.phrs.2008.02.006","volume":"57","author":"R Saraceno","year":"2008","unstructured":"Saraceno R, Schipani C, Mazzotta A, Esposito M, Direnzo L, Delorenzo A et al (2008) Effect of anti-tumor necrosis factor-\u03b1 therapies on body mass index in patients with psoriasis. Pharmacol Res 57(4):290\u2013295","journal-title":"Pharmacol Res"},{"issue":"15","key":"7649_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fphar.2020.00481","volume":"11","author":"O Patsalos","year":"2020","unstructured":"Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H (2020) Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol 11(15):481","journal-title":"Front Pharmacol"},{"issue":"3","key":"7649_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.orcp.2023.05.004","volume":"17","author":"H Kim","year":"2023","unstructured":"Kim H, Hong JY, Cheong S, Kang JH (2023) Impact of biologic agents on body weight and obesity-related disorders in patients with psoriasis: a nationwide population-based cohort study. Obes Res Clin Pract 17(3):210\u2013217","journal-title":"Obes Res Clin Pract"},{"issue":"6","key":"7649_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0961203311435266","volume":"21","author":"FX Wu","year":"2012","unstructured":"Wu FX, Luo XY, Wu LJ, Yang MH, Long L, Liu NT et al (2012) Association of chemokine CXCL12-3\u2032G801A polymorphism with systemic lupus erythematosus in a Han Chinese population. Lupus 21(6):604\u2013610","journal-title":"Lupus"},{"issue":"6","key":"7649_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.ijo.0803178","volume":"30","author":"WB Dr\u00f8yvold","year":"2006","unstructured":"Dr\u00f8yvold WB, Nilsen TIL, Kr\u00fcger O, Holmen TL, Krokstad S, Midthjell K et al (2006) Change in height, weight and body mass index: longitudinal data from the HUNT Study in Norway. Int J Obes (Lond) 30(6):935\u2013939","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"7649_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/archinte.1990.00390150135026","volume":"150","author":"DF Williamson","year":"1990","unstructured":"Williamson DF, Kahn HS, Remington PL, Anda RF (1990) The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 150(3):665\u2013672","journal-title":"Arch Intern Med"},{"issue":"8","key":"7649_CR31","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673","journal-title":"Arthritis Rheum"},{"issue":"6","key":"7649_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","volume":"33","author":"L Costa","year":"2014","unstructured":"Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P et al (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33(6):833\u2013839","journal-title":"Clin Rheumatol"},{"key":"7649_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41927-020-00138-3","volume":"4","author":"S Mantravadi","year":"2020","unstructured":"Mantravadi S, George M, Brensinger C, Du M, Baker JF, Ogdie A (2020) Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis. BMC Rheumatol 4:39","journal-title":"BMC Rheumatol"},{"issue":"12","key":"7649_CR34","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/ard.2009.125476","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Love TJ, Canning C, Schneeweiss S (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69(12):2114\u20132117","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7649_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40744-020-00206-7","volume":"7","author":"G Dal Bello","year":"2020","unstructured":"Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G (2020) Psoriatic arthritis and diabetes mellitus: a narrative review. Rheumatol Ther 7(2):271\u2013285","journal-title":"Rheumatol Ther"},{"doi-asserted-by":"crossref","unstructured":"Mehta P, Kharouf F, Abarza VC, Gao S, Cook RJ, Poddubnyy D, et al (2025) Exploring the impact of conventional and targeted DMARDs on body weight in patients with PsA. Rheumatology 64(9):5074\u20135080.","key":"7649_CR36","DOI":"10.1093\/rheumatology\/keaf277"},{"issue":"1","key":"7649_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/039463200902200124","volume":"22","author":"M Esposito","year":"2009","unstructured":"Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S (2009) Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 22(1):219\u2013225","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"16","key":"7649_CR38","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.282.16.1519","volume":"282","author":"AH Mokdad","year":"1999","unstructured":"Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP (1999) The spread of the obesity epidemic in the United States, 1991\u20131998. JAMA 282(16):1519\u20131522","journal-title":"JAMA"},{"issue":"1","key":"7649_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","volume":"116","author":"CS Fox","year":"2007","unstructured":"Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments. Circulation 116(1):39\u201348","journal-title":"Circulation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07649-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:11:46Z","timestamp":1762881106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07649-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7649"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07649-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was approved by the University Health Network Research Ethics Board (REB Study#: 08\u20130630). All individuals have provided written informed consent for this research study and its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval."}},{"value":"Dafna Gladman has received grants and\/or consulting fees from Abbvie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Novartis, Pfizer, UCB. Vinod Chandran has received research grants from AbbVie, Amgen, and Eli Lilly and has received honoraria for advisory board member roles from AbbVie, BMS, Eli Lilly, Fresenius Kabi, Janssen, Novartis and UCB. His spouse is an employee of AstraZeneca. All other authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}